+44 (0)20 3910 4640 info@symmetron.net
  • 🗨 We’re hiring!
Symmetron
  • Services
  • Therapeutic areas
  • The Team
  • Careers
  • Contact
Select Page

Economic evaluation of insertable cardiac monitors in detecting previously undiagnosed atrial fibrillation and subsequently moderating stoke risk in a high-risk population in the United Kingdom

by Symmetron | Jan 19, 2019

atrial fibrillation   Economic evaluation of insertable cardiac monitors in detecting previously undiagnosed atrial fibrillation and subsequently moderating stoke risk in a high-risk population in the United Kingdom Presented at ESC Congress. August 25-29, 2018....

Economic evaluation of insertable cardiac monitors to detect atrial fibrillation and subsequently moderate stroke risk in a high-risk population in the UK

by Symmetron | Jan 18, 2019

atrial fibrillation Economic evaluation of insertable cardiac monitors to detect atrial fibrillation and subsequently moderate stroke risk in a high-risk population in the UK Presented at ISPOR Europe.  November 10-14, 2018. Barcelona, Spain. Authors C. Rinciog, L....

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke

by Symmetron | Jan 18, 2019

atrial fibrillation   Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. (UK) International Journal of Stroke. 2016;11(3):302-12 Authors Diamantopoulos A, Sawyer LM, Lip GY, Witte KK, Reynolds MR,...

Pharmacoeconomic assessment of nintedanib for the treatment of idiopathic pulmonary fibrosis in the Greek healthcare system

by Symmetron | Jan 18, 2019

Idiopathic Pulmonary Fibrosis Pharmacoeconomic Assessment of Nintedanib For The Treatment of Idiopathic Pulmonary Fibrosis In The Greek Healthcare System Presented at ISPOR Europe. October 29 to November 2, 2016. Vienna, Austria. Authors Triaki G, Souliotis K, Bouros...

Cost-Effectiveness of nintedanib in idiopathic pulmonary fibrosis in the U.S.

by Symmetron | Jan 18, 2019

Idiopathic Pulmonary Fibrosis Cost-Effectiveness of Nintedanib in Idiopathic Pulmonary Fibrosis in the U.S. Presented at AMCP NEXUS. October 22-25, 2018. Orlando, USA Authors Rinciog C, Bermingham S, Cornic L, Diamantopoulos A, Fan Y  Process \ Qualitative and...
« Older Entries

Recent Comments

    Archives

    Categories

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Privacy Policy
    © 2019 Symmetron Ltd